NEK2 and hepatocellular carcinoma: In hepatocellular carcinoma (HCC), for example, NEK2 activates the transcription of downstream target genes through stabilizing β-catenin and promoting its translocation to the nucleus, consequently enhancing the sorafenib resistance in HCC cells (Deng et al., 2019).